Comtecmed - CURY 2009

CURY

Cury

Session 5:
Hormone Therapy for Prostate Cancer: Exploring
Current Controversies
Satellite Symposium by Astellas Pharma Europe Limited

Montorsi

Introduction
F. Montorsi, Italy

Irani

What is the added value of (neo) adjuvant hormone therapy?
J. Irani, France

Schulman

Continuous or intermittent hormone therapy in advanced prostate
cancer?
C. Schulman, Belgium

Berges

Quality of life of prostate cancer patients on hormone therapy:
Do we care enough?
R. Berges, Germany

Powerd by: